Format

Send to

Choose Destination
Clin Cancer Res. 2018 Sep 6. doi: 10.1158/1078-0432.CCR-18-0847. [Epub ahead of print]

A Phase II and Biomarker Study of Sorafenib Combined with Modified FOLFOX in Patients with Advanced Hepatocellular Carcinoma.

Author information

1
Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, Massachusetts. lgoyal@partners.org.
2
Harvard Medical School, Boston, Massachusetts.
3
Biostatistics Center, Massachusetts General Hospital, Boston, Massachusetts.
4
Dana-Farber Cancer Institute, Boston, Massachusetts.
5
Beth Israel Deaconess Medical Center, Boston, Massachusetts.
6
Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, Massachusetts.
7
Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts.
8
Steele Laboratories for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital Research Institute, Boston, Massachusetts.

Abstract

Purpose: Sorafenib is a standard first-line treatment for advanced hepatocellular carcinoma (HCC). The phase III SHARP trial showed a median time-to-progression (mTTP) of 5.5 months, overall response rate (ORR) of 2%, and median overall survival (mOS) of 10.7 months with sorafenib. FOLFOX4 has shown modest activity in advanced HCC. We evaluated the combination of sorafenib and modified (m)FOLFOX in a single-arm, multicenter phase II study.Experimental Design: The study included Child-Pugh A patients with advanced HCC and no prior systemic therapies. Patients received sorafenib 400 mg twice a day for 2 weeks, followed by concurrent mFOLFOX [5-fluorouracil (5-FU) 1,200 mg/m2/day for 46 hours, leucovorin 200 mg/m2, and oxaliplatin 85 mg/m2 biweekly]. The primary endpoint was mTTP with an alternative hypothesis of 7 months, and secondary endpoints included ORR, mOS, and circulating biomarkers.Results: The study enrolled 40 patients: HCV/EtOH/HBV, 43%/28%/13%; Child-Pugh A5, 70%. Notable grade 3/4 adverse events (AE) included AST/ALT elevation (28%/15%), diarrhea (13%), hyperbilirubinemia (10%), hand-foot syndrome (8%), and bleeding (8%). mTTP was 7.7 months [95% confidence interval (CI): 4.4-8.9], ORR 18%, and mOS 15.1 months (7.9-16.9). Sorafenib + mFOLFOX increased plasma PlGF, VEGF-D, sVEGFR1, IL12p70, and CAIX and CD4+ and CD8+ effector T lymphocytes and decreased plasma sVEGFR2 and s-c-KIT and regulatory T cells (Tregs). Shorter TTP was associated with high baseline sVEGFR1. Shorter TTP and OS were associated with increases in Tregs and CD56Dim natural killer (NK) cells after sorafenib alone and plasma sMET after combination treatment (all P < 0.05).Conclusions: Sorafenib + mFOLFOX met the prespecified endpoint with encouraging efficacy but moderate hepatotoxicity. Thus, this regimen may be effective in select patients with adequate liver reserve. Biomarker evaluations suggested a correlation between time-to-progression (TTP) and angiogenic biomarkers and circulating Tregs. Clin Cancer Res; 1-10. ©2018 AACR.

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center